38 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 38 of 38 clinical reviews.
A clinical guide to abaloparatide (Tymlos) for osteoporosis, covering mechanism, trial data from ACTIVE and ACTIVExtend, dosing, side effects, cost, and head-to-head comparisons with teriparatide, alendronate, risedronate, ibandronate, and zoledronic acid.
Alendronate's brand name is Fosamax, a once-weekly bisphosphonate cutting hip fracture risk about 51% and vertebral fracture risk about 47%, per the FIT trial.
A clinical comparison of alendronate (oral weekly) vs zoledronic acid (annual IV infusion) for osteoporosis, covering fracture-reduction data, dosing, side effects, and how both stack up against denosumab, teriparatide, abaloparatide, and romosozumab.
Bisphosphonates are effective for osteoporosis, but long-term use raises questions about atypical fractures, osteonecrosis of the jaw, and how to stop drugs like Prolia safely. Get evidence-based answers here.
A guide to atypical femoral fractures (AFFs), including their link to bisphosphonates and denosumab, osteonecrosis of the jaw, denosumab rebound on discontinuation, diagnosis, and management.
A guide to bisphosphonate drug holidays covering stopping criteria, duration by agent, fracture risk monitoring, denosumab scheduling, and vitamin D repletion dosing.
Compare bisphosphonates (alendronate, zoledronic acid) and denosumab (Prolia) for osteoporosis. Evidence-based analysis of efficacy, fracture reduction, side effects, cost, and switching protocols.
Bariatric surgery accelerates bone loss in every patient subgroup. Learn the mechanisms, monitoring schedule, supplement protocols, and when to start antiresorptive therapy, with evidence from named trials and clinical guidelines.
A comprehensive clinical guide to osteoporosis covering bone remodeling, DXA diagnosis, fracture risk, and treatments from bisphosphonates to hormone therapy, grounded in current evidence.
Aromatase inhibitors accelerate bone loss by suppressing estrogen. Learn evidence-based strategies to protect bone density during AI therapy, including bisphosphonates, denosumab, and lifestyle modifications.
Glucocorticoid-induced osteoporosis is the most common form of secondary osteoporosis. Learn how long-term steroid use damages bone, who needs treatment, and which medications protect against fractures.
Calcitonin cuts vertebral fracture risk by 33% in the PROOF trial, well below alendronate's 51% hip fracture reduction, making it a third-line osteoporosis option.
Complete guide to the denosumab (Prolia) every-6-month injection schedule, including timing windows, lab monitoring, vitamin D repletion, bisphosphonate transition protocols, and rebound fracture prevention.
Stopping denosumab without a transition plan triggers rapid, severe bone loss and a spike in vertebral fracture risk. Learn the mechanism, the clinical evidence, and the only proven prevention strategy.
Learn the difference between T-scores and Z-scores on a DEXA scan, what each number tells you about fracture risk, and when your doctor uses one over the other.
Evidence-based review of weighted vest training for bone density. Covers clinical trial results, optimal protocols, and how mechanical loading compares to pharmacotherapy for osteoporosis prevention.
A clinical comparison of romosozumab (Evenity) and teriparatide (Forteo) for osteoporosis, covering BMD gains, fracture reduction, dosing, side effects, cost, and sequencing strategies.
A detailed clinical comparison of teriparatide (Forteo) and abaloparatide (Tymlos) for osteoporosis, covering fracture data, dosing, side effects, cost, and how each fits into a broader treatment sequence.
Stopping Prolia (denosumab) without a transition plan can trigger rebound vertebral fractures within months. Learn the evidence-based protocol for safe discontinuation, including bisphosphonate bridging, monitoring timelines, and DEXA follow-up.
Prolia (denosumab) costs roughly $1,800 per injection without insurance. Learn about Medicare Part B coverage, copay assistance, and how Prolia pricing compares to bisphosphonates and anabolic agents like Evenity and Forteo.
A guide to ibandronate (Boniva) covering FDA-approved doses, fracture-risk data, head-to-head comparisons with alendronate, risedronate, zoledronic acid, and denosumab, plus monitoring protocols and switching criteria.
A clinical guide to insurance coverage for anabolic osteoporosis drugs including teriparatide (Forteo), abaloparatide (Tymlos), and romosozumab (Evenity), with costs, prior auth tips, and appeal strategies.
Collagen makes up roughly 30% of bone by weight, but does supplementing it improve bone density? We review the RCTs, compare collagen to standard osteoporosis therapies, and explain who may benefit.
Male osteoporosis affects roughly 2 million men in the U.S. and causes 80,000 hip fractures per year. Learn the causes, screening criteria, and FDA-approved treatments backed by clinical trial data.
Osteonecrosis of the jaw (ONJ) is a rare but serious complication of bisphosphonates and denosumab. Learn the real incidence, risk factors, prevention steps, and what to do if you develop ONJ while on osteoporosis treatment.
Osteopenia is a T-score of -1.0 to -2.5 on a DEXA scan. Learn how FRAX guides treatment plus calcium, vitamin D, and medication options.
A guide to osteoporosis covering bone density thresholds, DXA scanning, postmenopausal bone loss, male osteoporosis, steroid-induced disease, and FDA-approved treatments including bisphosphonates, denosumab, and romosozumab.
A complete clinical guide to Paget's disease of bone, covering pathophysiology, diagnostic criteria, bisphosphonate therapy, and how it differs from osteoporosis and osteopenia.
Postmenopausal bone loss accelerates rapidly after menopause due to estrogen withdrawal. Learn the science, screening timelines, drug options, and lifestyle strategies that protect bone density.
A comparison of denosumab (Prolia) vs bisphosphonates (alendronate, zoledronic acid, risedronate) covering efficacy, fracture risk, dosing, side effects, and how to switch safely.
A guide to raloxifene (Evista) for postmenopausal osteoporosis and breast cancer risk reduction, including dosing, side effects, and head-to-head comparisons with alendronate, risedronate, ibandronate, and zoledronic acid.
Complete clinical guide to risedronate (Actonel): doses, fracture-reduction data, side effects, and head-to-head comparisons with alendronate, ibandronate, zoledronic acid, and denosumab.
A clinical deep-dive into romosozumab (Evenity) for osteoporosis, including how it works, trial data, and how it stacks up against alendronate, risedronate, ibandronate, and zoledronic acid.
A guide covering who actually needs calcium and vitamin D supplements, safe dosing, bisphosphonate safety, how to stop Prolia, DEXA T-score vs Z-score, and whether weighted vests build bone density.
Glucocorticoid-induced osteoporosis is the most common secondary cause of bone loss. Learn how steroids damage bone, who is at risk, and what treatments the 2022 ACR guidelines recommend.
Teriparatide (Forteo) is an anabolic bone-building agent for severe osteoporosis. Learn how it works, who qualifies, expected BMD gains, side effects, cost, and how it compares to alendronate, risedronate, ibandronate, and zoledronic acid.
A clinical guide to vertebral compression fractures covering diagnosis, conservative management, vertebroplasty, kyphoplasty, and osteoporosis prevention strategies backed by trial data.
A guide to zoledronic acid (Reclast): how the annual IV infusion works, fracture-reduction data from HORIZON-PFT, dosing, side effects, and head-to-head comparisons with alendronate, risedronate, ibandronate, and denosumab.